The 3yr. follow-up results from the P-III trial evaluating Opdivo + CT vs CT alone in 358 patients with resectable stage IB to IIIA NSCLC, regardless of PD-L1 expression
The results showed sustained clinical benefits, 32% reduction in risk of disease recurrence, progression, or death with a median follow-up of 41.4mos., 3yr. EFS rate of 57% vs 43%, TTDM continued to favor Opdivo with CT with 3yr. landmark TTDM rates of 71% vs. 50%
OS remained immature, 78% vs 64% were alive @3yrs. The combination therapy continues to demonstrate improved EFS benefits in the explanatory analysis @3yrs. & safety profile was consistent with the primary analysis with no new safety signals, grade 3-4 treatment-related & surgery-related AEs (36% & 11% vs 38% & 15%), respectively
Ref: BMS | Image: BMS
Related News:- Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea
